Drug intelligence / Profile preview

Proxazole

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Proxazole is a small molecule described as a spasmolytic papaverine-like agent. It has been studied for its effects on blood flow, particularly increasing cerebral blood flow. Clinical investigations explored its potential in conditions such as cerebrovascular insufficiency, labor, obliterating arteriopathy of the lower limbs, EPH-gestosis, and acute renal insufficiency. However, studies in chronic renal failure indicated that proxazole was ineffective in improving renal function.

Other names: 3-alpha-Phenyl-propyl-5-beta-diethylaminoethyl-1,2,3-oxadiazoleProxazole citrate

Targets

mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on Proxazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proxazole.

Explore the full profile